Cipla’s Pithampur manufacturing facility gets warning letter from USFDA

20 Nov 2023 Evaluate

Cipla has received a warning letter on November 17, 2023 from United States Food and Drug Administration (USFDA) for the routine current Good Manufacturing Practices (cGMP) inspection conducted at its Pithampur manufacturing facility between February 6th -17th, 2023. This Warning Letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections.

The Company will respond to the Warning Letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1494.40 -10.65 (-0.71%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×